Dauntless Pharmaceuticals Inc., a biopharmaceutical company focused on the development of specialty drugs, has closed a $12 million Series A financing. The company was started by Joel Martin, co-founder, president and chief executive officer, and Sofinnova Ventures, the sole institutional investor in the Series A financing. Michael Powell, Sofinnova general partner, is a co-founder and will also serve as chairman. David Kabakoff, Sofinnova executive partner, will also serve on the company’s boar...